Stroke medicine is a group of drug of antihistamines , antiplatelet or anticoagulants which blood clots from forming and keeps existing blood clots from getting bigger and also prevent the platelets present in the blood from sticking together. Stroke is a serious, life-threatening medical condition that occurs when the blood supply to part of the brain is cut off. Stroke is the second leading cause of long-term disability in world. Worldwide, 15 million people suffer a stroke each year; one-third die and one-third are left permanently disabled and also 80% of deaths take place in low- and middle-income countries. Some of the stroke medicines are Acenocoumarol, Actilyse, Alteplase, Angettes, Asasantin, Aspirin, Aspirin/Dipyridamole, Atorvastatin, Bendroflumethiazide, Brilique, Caprin, Crestor, Dipyridamole, Fluvastatin, Heparin, sodium, Lescol Lipitor, Lipostat, Marevan, Nu-Seals, Persantin, Plavix, Pravastatin, Ramipril, Rosuvastatin Simvador, Simvastatin, Sinthrome ,Ticagrelor, Tritace, Warfarin and Zocor

OMICS International through its Open access initiatives is committed to make genuine and reliable contributions to the scientific community by publishing research work and conference paper related to such disorders. It is known that ConferenceSeries hosts over 700 edge peer reviewed Open Access Journals and organizes over more than 1000 Global Events annually. Its publishing group journals have over 5 million readers and the fame and success of the same can be attributed to the strong editorial board which contains over 75000+ eminent personalities that ensure a quality and quick review process checker.

Approximately 80 % of strokes can be prevented. Though some stroke risk factors are uncontrollable, such as age and race, other risk factors are in your control and making small lifestyle changes can reduce your stroke risk. Stroke kills almost 130,000 Americans each year that’s 1 out of every 20 deaths. Every year, more than 795,000 people in the United States have a stroke. In China, the prevalence of stroke ranges between 1.8% (rural areas) and 9.4% (urban areas).

According to the WHO, estimates the number of stroke events in EU countries, Iceland, Norway, and Switzerland is likely to increase from 1.1 million per year in 2000 to more than 1.5 million per year in 2025 solely because of the demographic changes. The estimated direct and indirect cost of stroke in the US for 2010 was $ 73.7 billion. The estimated cost of stroke in Europe in 2010 was approximately € 64.1 billion. In the 27 EU countries, total annual cost of stroke is estimated at €27 billion: €18.5 billion (68.5%) for direct and €8.5 billion (31.5%) for indirect costs. A further sum of €11.1 billion is calculated for the value of informal care. Including informal care in the total amount, percentages would change to 48.6% for direct, 22.3% for indirect and 29.1% for informal care costs. The National Audit Office report of the cost of stroke treatment is £7 billion per year. The research association of Alzheimer’s reported that the care cost for AD patients is $200 billion per year in 2012 and it is expected the cost is projected to rise to $1.1 trillion per year by 2050.